AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22285545 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 399 mg
Number of subjects: 138
Study 22285545 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 532 mg
Number of subjects: 138
Study 22285545 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine HCl 150 mg
Number of subjects: 138
Study 20385935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 12 mg daily plus vitamin A 15,000 IU/d
Number of subjects: 225
Study 20385935 — intervention group
Group type: COMPARATOR
Intervention: Control tablet plus vitamin A 15,000 IU/d
Number of subjects: 225
Study 17535827 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methyl prednisolone (Group B)
Number of subjects: 99
Study 17535827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (Group C)
Number of subjects: 99
Study 17535827 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 99
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (18 g/1,000 kcal, 3.5 servings of fruits and vegetables/1,000 kcal, 20% energy)
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among non-NSAID users
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among males who did not use NSAIDs
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among NSAID users
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among females who did not use NSAIDs
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among females who used NSAIDs
Number of subjects: 1905
Study 16214917 — intervention group
Group type: COMPARATOR
Intervention: NSAID use in control group
Number of subjects: 1905
Study 16214917 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use in intervention group
Number of subjects: 1905
Study 12142861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 24
Study 12142861 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 24
Study 12142861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10204898 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% articaine
Number of subjects: 10
Study 10204898 — intervention group
Group type: COMPARATOR
Intervention: 0.5% prilocaine
Number of subjects: 10
Study 8610766 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vaginal vault with two layers of continuous 3‐0 polyglactin suture
Number of subjects: 273
Study 8610766 — intervention group
Group type: COMPARATOR
Intervention: Open vaginal vault with a locking 3‐0 polyglactin suture
Number of subjects: 273
Study 2126131 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP/532-laser tonsillectomy
Number of subjects: 83
Study 2126131 — intervention group
Group type: COMPARATOR
Intervention: Traditional dissection/snare tonsillectomy
Number of subjects: 83
Study 434430 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory gases optimally warmed and humidified
Number of subjects: 55
Study 434430 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming up all perfused liquids in a water‐bath heat‐exchanger
Number of subjects: 55
Study 434430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenwal heat-exchanger
Number of subjects: 55
Study 434430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 31451273 — intervention group
Group type: EXPERIMENTAL
Intervention: SUITENA™ (a sweetener containing erythritol, xylitol, and Stevia)
Number of subjects: 6
Study 31451273 — intervention group
Group type: COMPARATOR
Intervention: Dextrose solution (control)
Number of subjects: 6
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme Learning Machine (ELM) for density estimation
Number of subjects: 0
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative distribution function estimation algorithm
Number of subjects: 0
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability density function estimation algorithm
Number of subjects: 0
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: F-discrepancy concept
Number of subjects: 0
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical analysis of ELM
Number of subjects: 0
Study 28103570 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation tests
Number of subjects: 0
Study 24471477 — intervention group
Group type: EXPERIMENTAL
Intervention: FSK0808 (200 µg/m² intravenous dose)
Number of subjects: 0
Study 24471477 — intervention group
Group type: COMPARATOR
Intervention: Gran® (200 µg/m² intravenous dose)
Number of subjects: 0
Study 24471477 — intervention group
Group type: EXPERIMENTAL
Intervention: FSK0808 (400 µg/m² subcutaneous dose)
Number of subjects: 0
Study 24471477 — intervention group
Group type: COMPARATOR
Intervention: Gran® (400 µg/m² subcutaneous dose)
Number of subjects: 0
Study 24471477 — intervention group
Group type: EXPERIMENTAL
Intervention: FSK0808 and Gran® (secondary endpoints)
Number of subjects: 0
Study 23871271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA) 20mg
Number of subjects: 1000
Study 23871271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1000
Study 23871271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA)
Number of subjects: 1000
Study 21976613 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids, γ-linolenic acid, and antioxidants
Number of subjects: 272
Study 21976613 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 272
Study 19076546 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT 300IR
Number of subjects: 628
Study 19076546 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT 500IR
Number of subjects: 628
Study 19076546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Italians (Study 1 and 2)
Number of subjects: 416
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Italians (Study 3 and 4)
Number of subjects: 416
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese (Study 3)
Number of subjects: 416
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese (Study 4)
Number of subjects: 416
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both languages (Study 5)
Number of subjects: 416
Study 16737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese participants (Study 5)
Number of subjects: 416
Study 12975689 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (six tablets of 333 mg/d for 12 weeks)
Number of subjects: 75
Study 12975689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (six tablets for 12 weeks)
Number of subjects: 75
Study 10636143 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 25 ng/kg/d) for 1 to 3 years (mean, 2.1+/‐0.9 years)
Number of subjects: 0
Study 10636143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10636143 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 25 ng/kg/d)
Number of subjects: 0
Study 10636143 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched female controls)
Number of subjects: 0
Study 8741718 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sessions of applied tension (AT5)
Number of subjects: 30
Study 8741718 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session of applied tension (AT1)
Number of subjects: 30
Study 8741718 — intervention group
Group type: COMPARATOR
Intervention: 1 session of tension-only (T1)
Number of subjects: 30
Study 1394816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) intravesical instillation therapy
Number of subjects: 0
Study 3935204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release choline theophyllinate
Number of subjects: 9
Study 3935204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29981855 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent feedback via the Communication Assessment Tool (CAT)
Number of subjects: 68
Study 29981855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no parent feedback)
Number of subjects: 68
Study 29981855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scores of both intervention and control groups
Number of subjects: 68
Study 29549007 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice
Number of subjects: 840
Study 29549007 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 840
Study 29549007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate Reduction (including nicotine replacement therapy in the form of gum)
Number of subjects: 840
Study 29549007 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Rate Reduction combined
Number of subjects: 840
Study 26811156 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping with irinotecan dose escalation
Number of subjects: 400
Study 26811156 — intervention group
Group type: COMPARATOR
Intervention: Conventional biweekly FOLFIRI regimen without UGT1A1 genotyping
Number of subjects: 400
Study 25342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set resistance training (1-SET)
Number of subjects: 30
Study 25342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-set resistance training (3-SET)
Number of subjects: 30
Study 21997547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 420
Study 21997547 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 420
Study 20502405 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX™ method
Number of subjects: 94
Study 20502405 — intervention group
Group type: EXPERIMENTAL
Intervention: History of vertebral fractures
Number of subjects: 94
Study 20502405 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fractures considered
Number of subjects: 94
Study 20502405 — intervention group
Group type: EXPERIMENTAL
Intervention: Densitometry results
Number of subjects: 94
Study 20502405 — intervention group
Group type: EXPERIMENTAL
Intervention: SQM assessment
Number of subjects: 94
Study 17478952 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pump infusion of 0.75% ropivacaine (12 mL initial dose, 6 mL/hour thereafter) in Group A
Number of subjects: 60
Study 17478952 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection of 0.75% ropivacaine (15 mL initial dose, 6 mL injected 80 min later) in Group B
Number of subjects: 60
Study 16235667 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF-glucose monitor; specific dosage and duration not mentioned.
Number of subjects: 0
Study 16235667 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; normal subjects and diabetic subjects were evaluated.
Number of subjects: 0
Study 12117087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream (once daily)
Number of subjects: 0
Study 12117087 — intervention group
Group type: COMPARATOR
Intervention: 5% fluorouracil cream (twice daily)
Number of subjects: 0
Study 11374329 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 64
Study 11374329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11374329 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen (capsule each night, as needed, or every third night)
Number of subjects: 64
Study 11374329 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated sleep
Number of subjects: 64
Study 9757979 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 113
Study 9757979 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogens (Control)
Number of subjects: 113
Study 9757979 — intervention group
Group type: COMPARATOR
Intervention: Histamine blockers (Disease-paired Control)
Number of subjects: 113
Study 8165534 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml administered through nasogastric tube)
Number of subjects: 99
Study 8165534 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 99
Study 8165534 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 99
Study 8165534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 3144198 — intervention group
Group type: COMPARATOR
Intervention: Nasal oxygen flow at 0 L/min
Number of subjects: 8
Study 3144198 — intervention group
Group type: COMPARATOR
Intervention: Nasal oxygen flow at 2 L/min
Number of subjects: 8
Study 3144198 — intervention group
Group type: COMPARATOR
Intervention: Nasal oxygen flow at 4 L/min
Number of subjects: 8
Study 3144198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine application
Number of subjects: 8
Study 29523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise before the learning task
Number of subjects: 33
Study 29523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after the learning task
Number of subjects: 33
Study 29523049 — intervention group
Group type: COMPARATOR
Intervention: Only learning task
Number of subjects: 33
Study 28439596 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic operation (LP)
Number of subjects: 206
Study 28439596 — intervention group
Group type: COMPARATOR
Intervention: Open operation (OP)
Number of subjects: 206
Study 26234554 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation plus diaphragm pacing with the NeuRx RA/4 Diaphragm Pacing System
Number of subjects: 74
Study 26234554 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation alone
Number of subjects: 74
Study 24093880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 0
Study 24093880 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training with low memory loads
Number of subjects: 0
Study 24093880 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 21570069 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant acupuncture for IVF
Number of subjects: 0
Study 21570069 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 0
Study 18670391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy (Group I)
Number of subjects: 179
Study 18670391 — intervention group
Group type: COMPARATOR
Intervention: FNAB or tumour wedge resection by VATS (Group II)
Number of subjects: 179
Study 17146316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (600 microg/d as picolinate)
Number of subjects: 16
Study 17146316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12716347 — intervention group
Group type: EXPERIMENTAL
Intervention: GR79236 (10 microg/kg i.v.)
Number of subjects: 12
Study 12716347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10922429 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (starting at 20 mg/day, titrated to 40 mg/day if cholesterol >5.2 mmol/L)
Number of subjects: 4444
Study 10922429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 10922429 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 4444
Study 8814503 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term high intensity (STHI) exercise at approximately 90-95% of VO2max
Number of subjects: 14
Study 8814503 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term high intensity (STHI) exercise
Number of subjects: 14
Study 1348751 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day)
Number of subjects: 10
Study 1348751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1348751 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 10
Study 30097419 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT intervention group
Number of subjects: 706
Study 30097419 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 706
Study 28499431 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPPO
Number of subjects: 36
Study 28499431 — intervention group
Group type: COMPARATOR
Intervention: Conventional ORIF
Number of subjects: 36
Study 26003436 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth behavioral treatment (TBT)
Number of subjects: 194
Study 26003436 — intervention group
Group type: COMPARATOR
Intervention: Education only (EO)
Number of subjects: 194
Study 23545912 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene foam, 0.005%
Number of subjects: 363
Study 23545912 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 363
Study 20877714 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) treatment for fever in the intervention group
Number of subjects: 3125
Study 20877714 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and appropriate treatment with amoxicillin for nonsevere pneumonia in the intervention group
Number of subjects: 3125
Study 20877714 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment for fever
Number of subjects: 3125
Study 20877714 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment for nonsevere pneumonia
Number of subjects: 3125
Study 19927606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous glycine phosphate and riboflavin added to school meals (28 mg of elemental iron and 1 mg of riboflavin per child per day) for 6 months.
Number of subjects: 136
Study 19927606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 136
Study 16306925 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (10 mg daily for 6 months)
Number of subjects: 915
Study 16306925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily for 6 months)
Number of subjects: 915
Study 16306925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron and zinc supplementation (10 mg iron + 10 mg zinc daily for 6 months)
Number of subjects: 915
Study 16306925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study 15451795 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 934
Study 15451795 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 934
Study 15451795 — intervention group
Group type: COMPARATOR
Intervention: Both
Number of subjects: 934
Study 11426091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg) with 1% lidocaine infiltration
Number of subjects: 40
Study 11426091 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 40
Study 11426091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 40
Study 11426091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg) with normal saline infiltration
Number of subjects: 40
Study 11426091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-lidocaine group (ketamine with 1% lidocaine infiltration)
Number of subjects: 40
Study 9435930 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports published in 1996
Number of subjects: 100
Study 9435930 — intervention group
Group type: COMPARATOR
Intervention: Reports published between 1979 to 1984
Number of subjects: 100
Study 8236005 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.5% ophthalmic solution
Number of subjects: 148
Study 8236005 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 148
Study 3822295 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage
Number of subjects: 51
Study 3822295 — intervention group
Group type: COMPARATOR
Intervention: Transurethral bladder drainage (Control)
Number of subjects: 51
Study 31574339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR results available in 24 hours (intervention group)
Number of subjects: 998
Study 31574339 — intervention group
Group type: COMPARATOR
Intervention: Standard care with multiplex PCR results available in 7 days (control group)
Number of subjects: 998
Study 29793518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, low-volume training
Number of subjects: 60
Study 29793518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, high-volume training
Number of subjects: 60
Study 29793518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, high-volume training
Number of subjects: 60
Study 29793518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised exercise)
Number of subjects: 60
Study 29793518 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 60
Study 27803392 — intervention group
Group type: EXPERIMENTAL
Intervention: 3K3A-APC (study drug), dosage not specified, used in conjunction with intra-arterial therapy (IAT)
Number of subjects: 51
Study 27803392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 51
Study 27803392 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol amendment allowing IAT
Number of subjects: 51
Study 22407197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose penicillin G
Number of subjects: 58
Study 22407197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose penicillin G
Number of subjects: 58
Study 22407197 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 58
Study 22889883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radial artery grafts (Group A)
Number of subjects: 53
Study 22889883 — intervention group
Group type: COMPARATOR
Intervention: Single radial artery grafts (Group B)
Number of subjects: 53
Study 20709856 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART lunch box intervention
Number of subjects: 1291